能夠治療武漢肺炎的藥物一直跑出來，令人振奮！我們積極防疫，爭取時間，以拖待變，是對的！
1、羥氯喹（hydroxychloroquine），必賴克廔(Plaquenil) ，原來用來治療瘧疾：
“But a 1,500-person trial, led by the University of Minnesota, began this week to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of COVID-19. Two other trials are studying the blood pressure drug losartan as a possible treatment for the disease.“
”Besides having a direct antiviral effect, hydroxychloroquine suppresses the production and release of proteins involved in the inflammatory complications of several viral diseases.“
“A French team on Tuesday said initial results from a 24-patient trial of hydroxychloroquine showed that 25% of patients given the drug still carried the coronavirus after six days, compared with 90% of patients given a placebo.
Tolar said he bought 1,500 doses of hydroxychloroquine for a "laughable" amount of money. "We don't need a multibillion-dollar investment. It is part of the beauty of this approach," he said.“
2、絡舒坦（losartan），原來用來降血壓：
“Also this week, the University of Minnesota launched two trials testing losartan - one to measure whether the hypertension drug reduces the risk of organ failure for COVID-19 patients who have been hospitalized, and another looking at whether the drug can limit the need for hospitalizations.
Losartan is an angiotensin receptor 1 (AT1R) blocker, which researchers say could play a role in blocking an enzyme used by the virus to bind to cells.“
3、瑞德西韋（Remdesivir）：
"Pharmaceutical companies are also working to develop treatments for COVID-19, including Gilead Sciences Inc's GILD.O experimental antiviral drug remdesivir, which is given to hospitalized patients via intravenous infusion over several days.
The New England Journal of Medicine earlier this month described how the drug was successfully used on the first patient infected by the novel coronavirus in the United States.
Results from a remdesivir trial in China could come early next month, while Gilead has begun two international trials of the drug that previously failed as a potential Ebola treatment. And the National Institutes of Health last month began testing it on patients in a U.S. trial."
4、Others:
"Companies including Regeneron Pharmaceuticals Inc REGN.O, Eli Lilly and Co LLY.N and Takeda Pharmaceutical Co 4502.T have begun to develop coronavirus treatment candidates, but human testing of their drugs has not yet started.
Anti-inflammatory drugs, like Regeneron's Kevzara and Roche Holding AG's ROG.S Actemra, have been used to treat the lung inflammation caused by COVID-19."
5、Nafamostat、camostat mesilate：
「日本東京大學研究團隊今天宣布，既有的急性胰臟炎治療藥物Nafamostat，可有效阻止武漢肺炎病毒在初期階段進入人體細胞，可能防止患者病情惡化，將在本月內進入臨床實驗以期早日實用化。」
「德國研究團隊以既有的經口胰臟炎藥物camostat mesilate 進行研究，發現可以阻病毒進入肺細胞，camostat mesilate和Nafamostat很類似，都是日本開發的藥物，具有抑制蛋白酶分解的即效性，德國研究團隊已於本月初發表這項研究結果。」
6、法維拉韋/法匹拉韋（favipiravir）：
「一項針對80位接受Fujifilm的法維拉韋（favipiravir）或阿維甘（Avigan）抗流感藥物的患者的研究發現，它比HIV藥物（lopinavir and ritonavir, marketed by AbbVie Inc. as Kaletra）提早一週從患者體內清除了該中國武漢冠狀病毒，並且與CT掃描顯示的患者胸部肺炎症狀改善有關。」
7、恢復期血漿（convalescent plasma）：
FDA說這是我們之前在疫情蔓延之際向其他國家提供過協助的領域，FDA已經就此研究了一段時間。
如果你曾暴露在新冠病毒之下，之後恢複，血液中不再有病毒，我們就可以收集（患者）血液。這是一種可能的療法，尚未被證實，我需要強調這一點。我們收集血液，濃縮——這是不含病毒的血液——然後将它用于治療其他病患，激發免疫反應，這可能對病患有利。
=================================
同意作者的論點，而且
可以治療中國肺炎（又稱武漢肺炎，是由COVID-19中國冠狀病毒所引起的）的瑞德西韋等抗病毒藥物的臨床試驗結果很快就會出來的，雖然中國二月底在武漢做的兩組臨床實驗，皆因爲找不到先前沒有使用他種藥物治療的病人（參
https://www.gbimonthly.com/2020/02/62568/ ，何況中國強調中西合併治療，而且同時有150組臨床實驗在進行），導致收案困難而進度遲緩，原訂4月底的解盲時間應該會推遲，但是我們台灣自己已經參加了3/3號開始的全球多國雙盲臨床實驗，美國上個月底也在進行該藥的另一臨床試驗，五月就會有結果，而六月就有機會量產，所以，請大家再撐一下。
